A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma

Journal of Immunotherapy
Dina M ElarajJames C Yang

Abstract

The use of antiangiogenic agents represents a promising strategy for the treatment of patients with metastatic renal cell carcinoma. Objective responses to single-agent thalidomide have been described, and a randomized study showed that bevacizumab (a neutralizing antibody against vascular endothelial growth factor) delayed time to progression of metastatic renal cancer. A pilot study combining these two agents was performed. Sequential cohorts of 10 and 12 patients (crossing over from placebo therapy in the aforementioned randomized bevacizuamab trial) were treated with low-dose bevacizumab alone or bevacizumab plus the maximum tolerated dose of thalidomide as determined by intrapatient escalation. Toxicity, objective responses, and time to progression were the endpoints of this study. Patients tolerated thalidomide and bevacizumab well, with more than 50% of patients escalating to at least 500 mg/d thalidomide. Grades 1 and 2 sensory neuropathy limited thalidomide dose escalation in 3 of 12 patients. The incidence of grades 3 and 4 toxicity was not different between patients treated with bevacizumab alone versus bevacizumab plus thalidomide. There were no objective responses and no difference in progression-free survival betw...Continue Reading

References

Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
May 1, 1994·Nature Genetics·J R GnarraF M Duh
Jul 1, 1998·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·F E KruseH E Völcker
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amnon ZismanArie S Belldegrun
Aug 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierA Laplanche
Nov 27, 2002·Investigational New Drugs·David R MinorLaurence Elias
Feb 6, 2003·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

May 6, 2006·Cancer Immunology, Immunotherapy : CII·Cécile GouttefangeasHans-Georg Rammensee
Mar 7, 2007·World Journal of Urology·Christoph W M ReuterArnold Ganser
Apr 20, 2006·International Journal of Clinical Oncology·Shigeru KandaHiroshi Kanetake
Apr 9, 2005·Current Opinion in Oncology·W Kimryn RathmellBrian I Rini
Jun 10, 2008·Neuro-oncology·Craig P CardenMark A Rosenthal
Mar 1, 2008·Biologics : Targets & Therapy·Chris Coppin
Jun 2, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Kostas N SyrigosKevin Harrington
Jan 5, 2011·Frontiers in Bioscience (Landmark Edition)·Jun CaiMichael E Boulton
May 22, 2010·Cancer Immunology, Immunotherapy : CII·Flávia Gomes de Góes RochaMaria Helena Bellini
Feb 16, 2005·Expert Opinion on Investigational Drugs·Aristotle Bamias, Meletios A Dimopoulos
Jan 13, 2006·Kidney International·R H Weiss, P-Y Lin
Feb 3, 2007·Urology·Brian R LaneSteven C Campbell
May 10, 2005·BJU International·Michael StaehlerMichael Siebels
Jan 31, 2006·Current Problems in Cancer·Erin A Donovan, Shivaani Kummar
Feb 16, 2005·Expert Opinion on Investigational Drugs·Dahlia T Lainer, Ernest Brahn
Feb 17, 2006·European Urology·Jean-Jacques PatardPatricia Fergelot
Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I Rini, Eric J Small
Jun 23, 2009·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Flavio L HeldweinGuy Vallancien
Apr 22, 2008·The Cochrane Database of Systematic Reviews·C CoppinT Wilt
Aug 2, 2007·Journal of Cellular Biochemistry·Shinichi SakamotoNatasha Kyprianou
Oct 8, 2008·American Journal of Clinical Oncology·Lauren C HarshmanSandy Srinivas
Jun 9, 2007·Expert Review of Anticancer Therapy·Jin-Young ParkRobert H Weiss
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James C Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.